Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

Jan 10, 2012, 04:08 ET from Reportlinker

 

 

NEW YORK, Jan. 10, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

http://www.reportlinker.com/p0749867/Influenza-Vaccine-Market-Opportunities-and-Challenges-Worldwide-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Influenza Vaccine Market Overview

Last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by the fear of an impending pandemic. As a result global influenza vaccine market has experienced phenomenal growth in recent years at a compound annual growth rate of more than 65% between 2008 and 2010. This growth was mainly driven by the global spread of H1N1 influenza. But in the year 2011 H1N1 pandemic flu vaccine market declined due to waning threat of swine flu disease. However seasonal influenza vaccine market is predicted to grow year on year and cross US$ 4 Billion by 2015.

From our research findings Unites States is the largest market for influenza vaccine market in 2010. In seasonal influenza vaccine brands like Fluarix & Flulaval had highest sales for 2010. Unlike some other pharmaceutical products, influenza vaccines are equally important in both developed and developing nations. In the developing countries, dealing with infectious diseases remains the highest priority in healthcare. It is predicted that in the next 5-6 years seasonal influenza vaccine sales would increase significantly.

Renub Research report entitled "Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast" critically examines the influenza vaccines market through a comprehensive review of information. This report provides market prospects, Key products detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and challenges, including revenue of key players from seasonal and H1N1 influenza vaccine as well as Strengths and Weakness analysis of key players in influenza vaccine segment.

This report examines the following markets for influenza vaccines:

• Global Influenza vaccine market (2005 - 2015)• Global Seasonal influenza vaccine market has been covered from (2003 – 2015)• Global Swine Flu (H1N1) influenza vaccine market has been covered from (2009 – 2012)• Top 7 Countries (United States, Germany, France, Italy, Spain, United Kingdom, Japan) seasonal vaccine market data from (2005 – 2015) • Top Brands Seasonal influenza vaccine market performance (Fluarix, Afluria, Flumist, Influvac) market performance and forecast• Top companies Swine Flu vaccine market performance (AstraZeneca, GlaxoSmithKline, Novartis, Sanofi-Pasteur)

Companies Analysis This section covers the key facts about the major companies that play an important role in Influenza Vaccine Market. The companies analyzed in this section are – GlaxoSmithKline, AstraZeneca, Novartis AG and Sanofi Pasteur. All the companies have been analyzed from three headings

1) Revenue of the company from influenza vaccines (swine flu & seasonal flu) 2) Strength of the company in influenza vaccine market 3) Weakness of the company in influenza vaccine market

Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.

Table of Contents 1. Executive Summary

2. Worldwide Influenza Vaccine & Future Market

2.1 Worldwide Seasonal Influenza Vaccine & Future Market

2.2 Global Swine Flu (H1N1) Influenza Vaccine & Future Market

2.2.1 Global Pandemic Influenza Occur (1918 - 2009)

2.2.2 Country wise Swine Flu Vaccine Dose Order (2009)

2.3 Merger and Acquisition in Influenza Vaccine Market

3. Geographical Distribution – Seasonal Influenza Vaccine Market (2005 to 2015) 3.1 United States Seasonal Influenza Vaccine Market3.2 Germany Seasonal Influenza Vaccine Market3.3 France Seasonal Influenza Vaccine Market3.4 Italy Seasonal Influenza Vaccine Market3.5 Spain Seasonal Influenza Vaccine Market3.6 United Kingdom Seasonal Influenza Vaccine Market3.7 Japan Seasonal Influenza Vaccine Market

4. Worldwide – Seasonal Influenza Vaccine Brand Market & Forecast Pipeline Analysis

4.1 Fluarix & Flulaval - Sales Performance & Forecast

4.2 Afluria - Past, Present and Future Sales Performance

4.3 FluMist – Past, Present & Future Sales Performance

4.4 Influvac - Sales Performance & Future Forecast

5. Swine Flu Vaccine Market Analysis – Competitive Landscape5.1 AstraZeneca Swine Flu Vaccine Sales Performance5.2 GlaxoSmithKline Swine Flu Vaccine Sales Performance5.3 Novartis Swine Flu Vaccines Sales Performance5.4 Sanofi-Pasteur Swine Flu Vaccine Sales Performance

6. Growth Drivers in the Influenza Vaccines Market

6.1 Growing Prevalence of Influenza

6.2 Emerging Vaccine Technologies

6.3 Effective Communication Strategies

6.4 Compliance with Vaccination

6.5 Vaccines most Cost Effective Means of Disease Prevention

7. Challenges for Influenza Vaccine Market7.1 Barriers to Optimal use of Licensed Vaccines7.1.1 Technical Obstacles7.1.2 Economic Obstacles7.1.3 Cultural Obstacles7.2 Complexity of Influenza Vaccine Development & Approval System Thwarts Product Development7.2.1 Legal Obstacles7.2.2 General Technical Barriers7.2.3 Economic Barriers7.2.4 Regulatory Barriers7.3 Shortening the Timeline for Vaccine Development

8. Company Analysis

8.1 GlaxoSmithKline

8.1.1 GSK Influenza Vaccine Revenue

8.1.2 GSK Influenza Vaccine Strengths

8.1.3 GSK Influenza Vaccine Weakness

8.2 AstraZeneca

8.2.1 AstraZeneca Influenza Vaccine Revenue

8.2.2 AstraZeneca Influenza Vaccine Strengths

8.2.3 Astrazeneca Influenza Vaccine Weakness

8.3 Novartis AG

8.3.1 Novartis AG Influenza Vaccine Strengths

8.3.2 Novartis AG Influenza Vaccine Weakness

8.4 Sanofi Pasteur

8.4.1 Sanofi-Pasteur Influenza Vaccine Revenue

8.4.2 Sanofi-Pasteur Influenza Vaccine Strengths

8.4.3 Sanofi-Pasteur Influenza Vaccine Weakness

List of Figures: Figure 2 1: Worldwide – Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 2 2: Worldwide – Forecast for Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 2 3: Worldwide – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 2 4: Worldwide – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 2 5: Worldwide – Swine Flu (H1N1) Influenza Vaccine Market & Forecast (Million US$), 2009 – 2011

Figure 3 1: United-States – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 2: United States – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 3: Germany – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 4: Germany – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 5: France – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 6: France – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 7: Italy – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 8: Italy – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 9: Spain – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 10: Spain – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 11: United Kingdom – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 12: United Kingdom – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015

Figure 3 13: Japan – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010

Figure 3 14: Japan – Forecast for Seasonal Influenza vaccine Market (Million US$), 2011 – 2015

Figure 4 1: Worldwide – Fluarix & Flulaval Vaccine Market (Million US$), 2007 – 2010

Figure 4 2: Worldwide – Forecast for Fluarix & Flulaval Vaccine Market (Million US$), 2011 – 2015

Figure 4 3: Worldwide – Afluria Vaccine Market (Million US$), 2008 – 2010

Figure 4 4: Worldwide – Forecast for Afluria Vaccine Market (Million US$), 2011 – 2015

Figure 4 5: Worldwide – Flumist Vaccine Market (Million US$), 2007 – 2010

Figure 4 6: Worldwide – Forecast for Flumist Vaccine Market (Million US$), 2011 – 2015

Figure 4 7: Worldwide – Influvac Vaccine Market (Million US$), 2006 – 2009

Figure 5 1: Astrazeneca – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2011

Figure 5 2: GSK – Swine Flu Vaccine Sales Performance & Future Forecast (Million US$), 2009 – 2011

Figure 5 3: Novartis – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2010

Figure 5 4: Sanofi Pasteur – Swine Flu Vaccine Sales Performance (Million US$), 2008 – 2010

Figure 9 1: Sanofi Pasteur – Influenza Vaccine Revenue (Million US$), 2007 – 2010

List of Tables: Table 2 1: Worldwide – Pandemic Influenza Vaccine Dose Orders (Million), 2009

Table 2 2: Worldwide – M&A Influenza Vaccine (Million US$), 2003, 2005, 2007, 2009 & 2010

Table 3 1: United States – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 2: Germany – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 3: France – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 4: Italy – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 5: Spain – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 6: United Kingdom – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 3 7: Japan – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050

Table 6 1: United States H1N1 – Related Hospitalizations and Deaths, By Age Group, April 2009February 13, 2010

Table 6 2: Improvement Strategies or Requirements – the Joint Commission and the Project's Collaborating Organizations

Table 6 3: Seasonal Influenza Vaccination Compliance

Table 6 4: Pandemic Flu Vaccination Compliance

Table 6 5: Major Literature Findings Relevant to Influenza

Table 8 1: GlaxoSmithKline – Influenza Vaccine Revenue (Million US$), 2007 – 2010

Table 8 2: AstraZeneca – Influenza Vaccine Revenue (Million US$), 2007 – 2010

To order this report:Drug and Medication Industry: Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com